智通财经网·2026-02-09 03:00Group 1 - China Biologic Products (01177) saw a stock increase of over 3%, reaching HKD 6.68 with a trading volume of HKD 149 million [1] - On February 9, China Biologic announced that its wholly-owned subsidiary, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd., has initiated a Phase III registration clinical trial for its innovative drug, LM-302, targeting CLDN18.2 positive advanced gastric and gastroesophageal junction adenocarcinoma [1] - LM-302 is the first CLDN18.2 ADC drug globally to complete patient enrollment in a Phase III clinical trial [1] Group 2 - At the 2025 American Society of Clinical Oncology (ASCO) annual meeting, Lixin Pharmaceutical presented new research data showing an objective response rate (ORR) of 65.9% and a disease control rate (DCR) of 85.4% in 41 evaluable patients treated with LM-302 combined with Toripalimab for gastric cancer [2] - In patients with CLDN18.2 expression ≥25%, the ORR reached 71.9% and the DCR was 96.9% [2] - The study indicated significant anti-tumor activity and manageable safety profiles for the LM-302 combination therapy in CLDN18.2 positive patients [2]